18:21 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Immune Design deprioritizes synovial sarcoma compound CMB305

Immune Design Corp. (NASDAQ:IMDZ) discontinued the Phase III SYNOVATE trial of CMB305 monotherapy to treat synovial sarcoma after an early analysis of a Phase II trial in the indication showed that CMB305 in combination with...
18:33 , Oct 10, 2018 |  BC Extra  |  Preclinical News

Quentis links ER stress, mitochondrial dysfunction with antitumor T cell activity

Researchers at Quentis Therapeutics Inc. (New York, N.Y.), Weill Cornell Medicine and Dana-Farber Cancer Institute uncovered a new mechanism of tumor immune evasion in which endoplasmic reticulum stress limits mitochondrial respiration and antitumor activity in...
19:34 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; colorectal cancer; melanoma Patient sample and mouse studies suggest inhibiting NFKB2 in combination with radiotherapy could help treat cancer. In glioblastoma patients treated with radiotherapy, high postmortem levels of NFKB2 mRNA in brain tissue...
19:34 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Mouse studies identified a peptide-based inhibitor of the LTBR-TRAF3 interaction that could help treat contact hypersensitivity. The fusion consists of a 28-amino acid, cell-penetrating peptide from the N-terminus of Drosophila antennapedia (Antp) and...
18:46 , Sep 7, 2018 |  BioCentury  |  Emerging Company Profile

Leveraging cross-linking

Lyvgen Biopharma Co. Ltd. is using its xLinkAb platform to develop mAbs that agonize T cell or dendritic cell co-stimulatory receptors with better safety and selectivity for tumors than competing mAbs. According to founder and CEO...
15:30 , Jul 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal; autoimmune disease

INDICATION: Colitis; Crohn disease Mouse studies suggest inhibiting LRRK2 could help treat colitis and Crohn disease. In dendritic cells from eight Crohn patients, four LRRK2 inhibitor tool compounds decreased levels of inflammatory cytokines compared with vehicle....
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
20:15 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Aivita raises $15M series B, considers Korean clinical trial for cancer therapy

Cellular therapy company Aivita Biomedical Inc. (Irvine, Calif.) raised $15 million on June 11 in a series B round led by sole South Korean investor SFC Co. Ltd. (KOSDAQ:112240). The round gives it a cash...
15:11 , Jun 8, 2018 |  BC Week In Review  |  Company News

Hookipa, Gilead partner to develop immunotherapies against HIV and HepB

Gilead Sciences Inc. (NASDAQ:GILD) gained exclusive, worldwide rights from Hookipa Biotech AG (Vienna, Austria) to use its TheraT and Vaxwave arenavirus-based vector technologies to develop immunotherapies for HBV and HIV infections. Hookipa is to receive $10...
01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...